Quick Answer
OS Therapies Inc reported Operating Income Loss of -$28.71 million for the year ending 2025.
- OS Therapies Inc showed a decrease of -321.3% in Operating Income Loss from 2024 to 2025.
- This data is from OS Therapies Inc's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$1.05 million | Q2 2023: -$1.52 million | Q3 2023: -$622.2 thousand | Q1 2024: -$630.2 thousand | Q2 2024: -$779.8 thousand | Q3 2024: -$2.44 million | Q1 2025: -$5.00 million | Q2 2025: -$4.84 million | Q3 2025: -$6.88 million.
- Over the full 3 years of available data (2023 to 2025), OS Therapies Inc's Operating Income Loss has declined by 561.0%.
- Historical annual values: Fiscal year 2025: -$28.71 million | Fiscal year 2024: -$6.81 million | Fiscal year 2023: -$4.34 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: